(Q30303941)

16 June 2017

1 reference

title

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease (English)

1 reference

16 June 2017

1 reference

1 reference

Bennett JP Jr

1

1 reference

16 June 2017

Piercey MF

series ordinal

2

1 reference

16 June 2017

publication date

1 February 1999

1 reference

Journal of the Neurological Sciences

16 June 2017

published in

1 reference

16 June 2017

volume

163

1 reference

16 June 2017

issue

1

1 reference

16 June 2017

page(s)

25-31

1 reference

Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

16 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Molecular diversity of the dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Depression and Parkinson's disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

The neostriatal mosaic: multiple levels of compartmental organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Antidepressant effects of pramipexole, a novel dopamine receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Attempts to obtain neuroprotection in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Dopamine Auto- and Postsynaptic Receptors: Electrophysiological Evidence for Differential Sensitivity to Dopamine Agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

Pharmacological approaches to counter the toxicity of Dopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900307-4

10.1016/S0022-510X(98)00307-4

7 January 2021

Identifiers

DOI

1 reference

16 June 2017

1 reference